Loading...
Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial
Lisdexamfetamine dimesylate (LDX) is a long-acting, prodrug stimulant therapy for patients with attention-deficit/hyperactivity disorder (ADHD). This randomized placebo-controlled trial of an optimized daily dose of LDX (30, 50 or 70 mg) was conducted in children and adolescents (aged 6–17 years) wi...
Na minha lista:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Springer Berlin Heidelberg
2013
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3918120/ https://ncbi.nlm.nih.gov/pubmed/23708466 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00787-013-0421-y |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|